← Leaderboards
Flavio Da Silva Emery
University Of Sao Paulo
$329,404
Attributed
$658,808
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $134.9K · FY2021–25$200K$150K$100K$50K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$658,808 · 1
By mechanism
R01$658,808 · 1
Top collaborators
- Maria Cristina Nonato5 shared
Most similar at University Of Sao Paulo
Same institution · by research overlap
- Maria Cristina Nonato$329,404
Others in their field
Other Emerging Leaders on “Acrylamides”
- Maisie Ky Lo · Stanford University$6,822,980
- Liangcai Gu · University Of Washington$2,788,050
- Taylor H Ware · University Of Texas Dallas$2,068,616
- Daniel Alge · Texas Engineering Experiment Station$1,605,517
- Ana Paula Piovezan Fugolin · Oregon Health & Science University$963,049
- Mukesh Kumar Gupta · Vanderbilt University$956,556
Research focus
AcrylamidesAcuteActive SitesAnabolismAnimal Disease ModelsAntiparasitic AgentsAffectBindingBloodBrazilCell Culture TechniquesCellsChagas DiseaseChemical StructureChronicChronic PhaseCollaborationsCommunitiesComplexComputational ChemistryComputer AssistedComputer ModelsCountryCysteine
Grant awards (5)
Validation of Trypanosoma cruzi dihydroorotate dehydrogenase as a drug target for Chagas´disease.$130,084
R01 · FY2025 · AI
Validation of Trypanosoma cruzi dihydroorotate dehydrogenase as a drug target for Chagas´disease.$130,928
R01 · FY2024 · AI
Validation of Trypanosoma cruzi dihydroorotate dehydrogenase as a drug target for Chagas´disease.$130,474
R01 · FY2023 · AI
Validation of Trypanosoma cruzi dihydroorotate dehydrogenase as a drug target for Chagas´disease.$132,461
R01 · FY2022 · AI
Validation of Trypanosoma cruzi dihydroorotate dehydrogenase as a drug target for Chagas´disease.$134,861
R01 · FY2021 · AI